US 11,654,104 B2
Use of IL-22 dimer in manufacture of a medicament for intravenous administration
Xiaoqiang Yan, Shanghai (CN); Cheng Huang, Shanghai (CN); Dongdong Wu, Shanghai (CN); Kaiyang Tang, Shanghai (CN); and Yuliang Huang, Shanghai (CN)
Assigned to Evive Biotechnology (Shanghai) Ltd, Shanghai (CN)
Filed by Evive Biotechnology (Shanghai) Ltd, Shanghai (CN)
Filed on Dec. 10, 2019, as Appl. No. 16/709,833.
Application 16/709,833 is a continuation of application No. 15/034,859, granted, now 10,543,169, previously published as PCT/CN2014/090520, filed on Nov. 6, 2014.
Claims priority of application No. 201310549838.1 (CN), filed on Nov. 7, 2013.
Prior Publication US 2020/0155448 A1, May 21, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); C07K 14/54 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/0019 (2013.01) [A61K 38/20 (2013.01); C07K 14/54 (2013.01)] 19 Claims
1. A method of treating a disease in a human individual, comprising intravenously administering to the human individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 μg/kg to about 200 μg/kg, wherein the IL-22 dimer comprises two monomeric subunits, wherein each monomeric subunit comprises an IL-22 domain and a dimerization domain, wherein the dimerization domain comprises the CH2 and CH3 domains of human IgG, and wherein the disease is liver disease, Parkinson's disease, or stroke.